AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28847532 — intervention group
Group type: COMPARATOR
Intervention: Controlled energy availability (CON; 45kcal·kgLBM‐1·d‐1)
Number of subjects: 22
Study 25811674 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) 70 mL (6 mmol nitrate)
Number of subjects: 11
Study 25811674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted BR)
Number of subjects: 11
Study 24268099 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-hospital-based treatment programme combining individual and group psychotherapy in a step-down format
Number of subjects: 107
Study 24268099 — intervention group
Group type: COMPARATOR
Intervention: Outpatient individual psychotherapy at a specialist practice
Number of subjects: 107
Study 20642462 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Drawing: Hospital (CD:H) score
Number of subjects: 54
Study 20642462 — intervention group
Group type: COMPARATOR
Intervention: Frankl scale
Number of subjects: 54
Study 20642462 — intervention group
Group type: COMPARATOR
Intervention: SEM scale
Number of subjects: 54
Study 19813463 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam patch (14 mg, 1%, applied once daily)
Number of subjects: 180
Study 19813463 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam cream (1%, applied three times a day)
Number of subjects: 180
Study 19813463 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (applied once daily)
Number of subjects: 180
Study 19813463 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam patch vs Piroxicam cream
Number of subjects: 180
Study 19813463 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam patch vs Piroxicam cream (intermediate visit, day 4)
Number of subjects: 180
Study 17448820 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg subcutaneously once daily for 10 days
Number of subjects: 1762
Study 17448820 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 U subcutaneously every 12 h for 10 days
Number of subjects: 1762
Study 17448820 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1762
Study 17448820 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 1762
Study 15100670 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal allergic rhinitis patients
Number of subjects: 50
Study 15100670 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 50
Study 11570706 — intervention group
Group type: EXPERIMENTAL
Intervention: QSART
Number of subjects: 31
Study 11570706 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR
Number of subjects: 31
Study 9663476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone treatment
Number of subjects: 79
Study 8005549 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral placebo
Number of subjects: 56
Study 8005549 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 56
Study 8005549 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen withdrawal test responsive patients
Number of subjects: 56
Study 8005549 — intervention group
Group type: COMPARATOR
Intervention: Progestogen withdrawal test nonresponsive patients
Number of subjects: 56
Study 2908303 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50mg
Number of subjects: 0
Study 2908303 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 100mg
Number of subjects: 0
Study 2908303 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 400mg
Number of subjects: 0
Study 2908303 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160mg
Number of subjects: 0
Study 2908303 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80mg plus Hydralazine 50mg
Number of subjects: 0
Study 2908303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine plus Propranolol 80mg
Number of subjects: 0
Study 2908303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor and isometric exercise
Number of subjects: 0
Study 2908303 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 2908303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31188820 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 369
Study 31188820 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookworm infection
Number of subjects: 369
Study 31188820 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated IL-6, IL-10, and CXCL8 in cord blood
Number of subjects: 369
Study 31188820 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated sTNFRI in cord blood and IL-5 in placental blood
Number of subjects: 369
Study 28166743 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular point-of-care testing using the FilmArray Respiratory Panel
Number of subjects: 0
Study 28166743 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 0
Study 25408122 — intervention group
Group type: EXPERIMENTAL
Intervention: Center of Rotation (COR) measurement for L4 motion segment in y axis
Number of subjects: 66
Study 25408122 — intervention group
Group type: EXPERIMENTAL
Intervention: Center of Rotation (COR) measurement for L5 motion segment in y axis
Number of subjects: 66
Study 24289509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 700
Study 24289509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 21611733 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive interpretation training
Number of subjects: 170
Study 21611733 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control condition
Number of subjects: 170
Study 18381903 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (15 or 30 mg/day)
Number of subjects: 384
Study 18381903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 16449030 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics, aminoglycosides, neuromuscular blockers (NMB), and vancomycin (50 received vancomycin)
Number of subjects: 81
Study 16449030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dosages and duration of use of diuretics, NMB, vancomycin, and overlap of diuretics with NMB, aminoglycosides, and vancomycin
Number of subjects: 81
Study 16449030 — intervention group
Group type: COMPARATOR
Intervention: Markers of illness severity
Number of subjects: 81
Study 16449030 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycosides
Number of subjects: 81
Study 12914886 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 0
Study 12914886 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10899732 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 448
Study 10899732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study 9179560 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g dispersible tablet form of amoxicillin (B)
Number of subjects: 12
Study 9179560 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g dispersible tablet in suspension form (C)
Number of subjects: 12
Study 9179560 — intervention group
Group type: COMPARATOR
Intervention: 1 g standard reference formulation (A)
Number of subjects: 12
Study 1564142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaseline Petroleum Jelly (VPJ)
Number of subjects: 0
Study 1564142 — intervention group
Group type: COMPARATOR
Intervention: Untreated sites
Number of subjects: 0
Study 4018467 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (L) - bolus of 1 mg/kg followed by an infusion of 10 mg/min for 20 minutes and thereafter of 1.5 mg/min
Number of subjects: 25
Study 4018467 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (A) - bolus of 5 mg/kg and an eventual repeat dose of 150 mg followed by an infusion of 1.8 g/24 h
Number of subjects: 25
Study 4018467 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (L)
Number of subjects: 25
Study 4018467 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (A)
Number of subjects: 25
Study 29317118 — intervention group
Group type: EXPERIMENTAL
Intervention: PXVX0200 (1 × 10^9 CFU)
Number of subjects: 3146
Study 29317118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 3146
Study 29317118 — intervention group
Group type: EXPERIMENTAL
Intervention: PXVX0200
Number of subjects: 3146
Study 29317118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3146
Study 26749407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 1000mg twice daily added to glimepiride
Number of subjects: 873
Study 26749407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 1000mg twice daily added to metformin
Number of subjects: 873
Study 24878030 — intervention group
Group type: EXPERIMENTAL
Intervention: G3 on pre-hospital ECG
Number of subjects: 401
Study 24878030 — intervention group
Group type: EXPERIMENTAL
Intervention: G2->G2
Number of subjects: 401
Study 24878030 — intervention group
Group type: EXPERIMENTAL
Intervention: G2->G3
Number of subjects: 401
Study 24878030 — intervention group
Group type: EXPERIMENTAL
Intervention: G3->G3
Number of subjects: 401
Study 24878030 — intervention group
Group type: COMPARATOR
Intervention: G3
Number of subjects: 401
Study 24878030 — intervention group
Group type: COMPARATOR
Intervention: G2
Number of subjects: 401
Study 23025057 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week peginterferon alpha-2a (180 microg/week) plus ribavirin therapy (group A)
Number of subjects: 102
Study 23025057 — intervention group
Group type: COMPARATOR
Intervention: 48-week peginterferon alpha-2a (180 microg/week) plus ribavirin therapy (group B)
Number of subjects: 102
Study 20434863 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention for smoking cessation including spirometric testing and feedback (approximately 20 min)
Number of subjects: 267
Study 17637912 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimney woodstove intervention
Number of subjects: 120
Study 17637912 — intervention group
Group type: COMPARATOR
Intervention: Traditional open wood fire
Number of subjects: 120
Study 17637912 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved stove intervention
Number of subjects: 120
Study 17637912 — intervention group
Group type: COMPARATOR
Intervention: Chimney woodstove intervention (before-and-after comparison)
Number of subjects: 120
Study 15691684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 microg/kg per min)
Number of subjects: 32
Study 15691684 — intervention group
Group type: COMPARATOR
Intervention: Control (no dobutamine)
Number of subjects: 32
Study 12107618 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ritanserin
Number of subjects: 22
Study 12107618 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg/kg mCPP
Number of subjects: 22
Study 12107618 — intervention group
Group type: COMPARATOR
Intervention: mCPP
Number of subjects: 22
Study 10460529 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemispheric-synchronised sounds
Number of subjects: 76
Study 10460529 — intervention group
Group type: COMPARATOR
Intervention: Classical music
Number of subjects: 76
Study 10460529 — intervention group
Group type: COMPARATOR
Intervention: Blank tape
Number of subjects: 76
Study 7876865 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F] fluorodeoxyglucose‐PET (FDG‐PET)
Number of subjects: 39
Study 7876865 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 39
Study 7876865 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and PET
Number of subjects: 39
Study 2404020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic sequential-compression boots
Number of subjects: 119
Study 2404020 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 119
Study 47348 — intervention group
Group type: EXPERIMENTAL
Intervention: Group classes utilizing audiovisual teaching techniques
Number of subjects: 45
Study 47348 — intervention group
Group type: COMPARATOR
Intervention: Traditional bedside manner
Number of subjects: 45
Study 30824825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis patients
Number of subjects: 160
Study 30824825 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 160
Study 28436395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 200 mg GSH
Number of subjects: 45
Study 28436395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 100 mg GSH
Number of subjects: 45
Study 28436395 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo (saline)
Number of subjects: 45
Study 25251411 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel applied to one-half of the sockets
Number of subjects: 45
Study 25251411 — intervention group
Group type: COMPARATOR
Intervention: Control (no chlorhexidine gel)
Number of subjects: 45
Study 23995467 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative teaching strategies
Number of subjects: 209
Study 21281463 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 80 mg/m2 i.v., LV 200 mg/m2, 5FU 450 mg/m2 bolus (Arm A)
Number of subjects: 873
Study 21281463 — intervention group
Group type: COMPARATOR
Intervention: Leucovorin 200 mg/m2 and 5FU 500 mg/m2 i.v. bolus (Arm B)
Number of subjects: 873
Study 19100248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CyA)
Number of subjects: 35
Study 19100248 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 35
Study 16733624 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of calcium daily
Number of subjects: 0
Study 16733624 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15359015 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective entreaty
Number of subjects: 160
Study 15359015 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical referendum
Number of subjects: 160
Study 15359015 — intervention group
Group type: COMPARATOR
Intervention: Real payment referendum
Number of subjects: 160
Study 10862195 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation program including continuous thoracic epidural analgesia, enforced early mobilization, and early enteral nutrition with a planned 48‐hour postoperative hospital stay.
Number of subjects: 60
Study 10862195 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned, but implied standard postoperative care with longer hospital stay.
Number of subjects: 60
Study 9347367 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSV (BiPAP)
Number of subjects: 42
Study 9347367 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 42
Study 8155035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline at 2000 mg/d
Number of subjects: 0
Study 8155035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2872806 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 133
Study 2872806 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 133
Study 2872806 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 133
Study 2872806 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin plus Hydrochlorothiazide
Number of subjects: 133
Study 30458866 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 0
Study 30458866 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium/olodaterol (TIO/OLO) 5/5 mcg
Number of subjects: 0
Study 26599131 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 1080
Study 26599131 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 1080
Study 24377455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayberry juice (250 mL twice daily for 4 weeks)
Number of subjects: 44
Study 24377455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22210566 — intervention group
Group type: EXPERIMENTAL
Intervention: intralipid/heparin infusion
Number of subjects: 38
Study 22210566 — intervention group
Group type: EXPERIMENTAL
Intervention: high-fat meal
Number of subjects: 38
Study 20082173 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training programs
Number of subjects: 0
Study 20082173 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical workload and overuse of facilitative communication skills
Number of subjects: 0
Study 18343810 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal aspiration of hydrosalpinx under antibiotics cover
Number of subjects: 66
Study 18343810 — intervention group
Group type: COMPARATOR
Intervention: No aspiration (control group)
Number of subjects: 66
Study 16266355 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (QD)
Number of subjects: 348
Study 16266355 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice daily (BID)
Number of subjects: 348
Study 16266355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 16266355 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 348
Study 16266355 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 348
Study 12443948 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected forward perturbations (FP) during gait
Number of subjects: 0
Study 10343535 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based exercise programme (n = 113)
Number of subjects: 191
Study 10343535 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, n = 78)
Number of subjects: 191
Study 8949694 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lipid emulsion
Number of subjects: 75
Study 8949694 — intervention group
Group type: COMPARATOR
Intervention: 20% lipid emulsion
Number of subjects: 75
Study 1827008 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 160
Study 1827008 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 160
Study 6123638 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 degrees reverse Trendelenburg position
Number of subjects: 10
Study 6123638 — intervention group
Group type: COMPARATOR
Intervention: Semi-orthopnoeic position (control)
Number of subjects: 10
Study 31563697 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LE) combined with low-dose gonadotropins using the multiple-dose GnRH-antagonist protocol
Number of subjects: 51
Study 31563697 — intervention group
Group type: COMPARATOR
Intervention: Low-dose gonadotropins using the multiple-dose GnRH-antagonist protocol (Control Group A)
Number of subjects: 51
Study 31421524 — intervention group
Group type: EXPERIMENTAL
Intervention: Consume 3 dairy servings/day
Number of subjects: 3
Study 31421524 — intervention group
Group type: EXPERIMENTAL
Intervention: Consume ≥ 4 servings/d
Number of subjects: 3
Study 31421524 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 27037817 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered as short intravenous infusion of 1-2 µg/kg in 10 min
Number of subjects: 39
Study 27037817 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 39
Study 26063001 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynocular colposcope
Number of subjects: 123
Study 26063001 — intervention group
Group type: COMPARATOR
Intervention: Stationary colposcope
Number of subjects: 123
Study 26063001 — intervention group
Group type: EXPERIMENTAL
Intervention: Punch biopsy
Number of subjects: 123
Study 26063001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 123
Study 26063001 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynocular and stationary colposcope
Number of subjects: 123
Study 23375053 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 60
Study 23375053 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional brackets
Number of subjects: 60
Study 23375053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treated groups (self-ligating and conventional)
Number of subjects: 60
Study 23375053 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 21632986 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 0
Study 19101312 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermogard system
Number of subjects: 38
Study 19101312 — intervention group
Group type: COMPARATOR
Intervention: Conventional warming
Number of subjects: 38
Study 16213663 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients (hypercortisolemic)
Number of subjects: 29
Study 16213663 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients (normocortisolemic)
Number of subjects: 29
Study 16213663 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 29
Study 16213663 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocortisolemic patients
Number of subjects: 29
Study 16213663 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercortisolemic patients
Number of subjects: 29
Study 15558380 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Practice (PP)
Number of subjects: 39
Study 15558380 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery-based Mental Practice (MP)
Number of subjects: 39
Study 15558380 — intervention group
Group type: COMPARATOR
Intervention: No Practice (NP)
Number of subjects: 39
Study 11753959 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy (ALT) - 4 cycles of intravenous cisplatin (20 mg/m² for 5 days) and 5-fluorouracil (200 mg/m² for 5 days) alternated with three 2-week courses of radiotherapy (20 Gy per course, 2 Gy per day, 5 days per week).
Number of subjects: 136
Study 11753959 — intervention group
Group type: COMPARATOR
Intervention: Partly accelerated radiotherapy (PA‐RT) - 75 Gy/40 fractions in 6 weeks.
Number of subjects: 136
Study 9433591 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage analysis using MAPMAKER/SIBS and SIBPAL program
Number of subjects: 0
Study 9433591 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis using residuals of Q1 and Q3
Number of subjects: 0
Study 8335014 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa vaccine
Number of subjects: 218